Remdesivir
Remdesivir (GS-5734) is an adenine derivative phosphoramidate prodrug
with a chemical structure similar to that of tenofovir alafenamide, an
approved inhibitor of HIV reverse transcriptase. Remdesivir has broad-
effects in cell cultures and animal models against RNA viruses, such as
- MERS and SARS, and has been checked for Ebola in a clinical trial. A
recent research confirmed that Remdesivir inhibited 2019-nCoV, when
tested in concentrations of EC50 = 0.77 μM in Vero E6 cells [10] One
US patient with 2019-nCoV was reported to get recovered after receiving
intravenous remdesivir in January 6, as trials in patients with
2019-nCoV (NCT04252664 and NCT04257656) were initiated in early February
to evaluate intravenous Remdesivir (200 mg on day 1 and 100 mg once
daily for 9 days), with estimated completion dates in April 2020
[11]. Notably, Remdesivir (EC50 = 0.77 μM; CC50 > 100
μM; SI > 129.87) at low-micromolar concentration,
effectively blocked virus infection and showed high SI [12].
Preliminary data suggested that Remdesivir also effectively blocked
virus infection in a human cell line (Huh-7 cells of human liver
cancer), which is immune to 2019-nCoV and currently, it is in the Phase
III of clinical trial established by China.